ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN: GLOBAL, SOUTH ASIAN, AND CENTRAL ASIAN PERSPECTIVES

Krishna Badal

Authors

Krishna Badal MBBS, MD Associate Professor, Department of Pediatrics, Faculty of International Students, Asia International University

Keywords:

Childhood acute lymphoblastic leukemia (ALL); Pediatric leukemia; epidemiology; South Asia; Central Asia; Survival outcomes; Supportive care; Pediatric oncology; Low- and middle-income countries (LMICs).

Abstract

Acute lymphoblastic leukemia (ALL) is the leading childhood cancer worldwide. Over recent decades, survival from pediatric ALL has risen dramatically in highincome countries due to riskadapted combination chemotherapy, robust supportive care, and coordinated clinical trial networks. However, striking disparities persist between and within regions, particularly in South Asia and Central Asia, where late presentation, treatment abandonment, and limited diagnostic and therapeutic capacity remain major obstacles. This review summarizes the global epidemiology and biology of childhood ALL, outlines treatment outcomes and healthsystem constraints, and examines specific challenges and opportunities in South Asia and Central Asia.

References

Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015 Oct 15;373(16):1541–52.

Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015 Jan 10;33(27):2938–48.

Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(11):2524–39.

Gupta S, Howard SC, Hunger SP, Antillon FG, Metzger ML, Israels T, et al. Treating childhood cancer in low- and middle-income countries. In: Gelband H, Jha P, Sankaranarayanan R, Horton S, editors. Cancer: disease control priorities. 3rd ed. Vol. 3. Washington (DC): World Bank; 2015. p. 121–46.

Ward ZJ, Yeh JM, Bhakta N, Frazier AL, Girardi F, Atun R. Estimating the total incidence of global childhood cancer: a simulation-based analysis. Lancet Oncol. 2019 Apr;20(4):483–93.

Greaves M. A causal mechanism for childhood acute lymphoblastic leukaemia. Nat Rev Cancer. 2018 Aug;18(8):471–84.

Walsh KM, de Smith AJ, Chokkalingam AP, Metayer C, Wiemels JL. Risk of childhood acute lymphoblastic leukemia: genetic susceptibility and environmental exposures. Transl Cancer Res. 2015;4(2):171–82.

Schafer ES, Hunger SP. Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults. Nat Rev Clin Oncol. 2011 Apr;8(7):417–24.

Moorman AV. New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2016 Jun;101(4):407–16.

Howard SC, Zaidi A, Cao X, Weil O, Bey P, Levine JM. The Childhood Cancer Burden and the Sustainable Development Goals. Cancer. 2020 Apr 1;126(6):1395–406.

Ma X, Pui CH. Late effects of treatment in childhood acute lymphoblastic leukemia and lymphoma. Clin Lymphoma Myeloma Leuk. 2011;11(3):205–12.

Arora RS, Eden T, Kapoor G. Epidemiology of childhood cancer in India. Indian J Cancer. 2009 Apr–Jun;46(4):264–73.

Kulkarni KP, Marwaha RK, Trehan A, Bansal D. Survival outcome in childhood ALL: experience from a tertiary care center in North India. Indian Pediatr. 2010;47(7):607–12.

Sultan I, Khalil S, Al-Suliman A, Sultan A, Qaddoumi I. Pediatric acute lymphoblastic leukemia: current epidemiology and outcome in developing countries. Pediatr Hematol Oncol. 2009;26(2):89–98.

Howard SC, Metzger ML, Wilimas JA, Quintana Y, Pui CH, Robison LL, et al. Childhood cancer epidemiology in low-income countries. Cancer. 2008;112(3):461–72.